CD274 and cancer: The results presented in this study demonstrate that FEGCG/Zn can act as both PD‐L1 inhibitor and carrier for immune‐biomolecule delivery and cell‐based delivery, and has potential as an effective delivery platform for enhanced cancer therapy.